A medium-sized pharmaceutical company was preparing to add a broader indication to a product already marketed in several rare indications in the US market. Ascenian was charged with identifying access and (net) pricing challenges and developing risk mitigation strategies.


Ascenian’s core consulting team, which included a former high-ranking official at a top US payer, identified key challenges and potential solutions. We proposed and refined several scenarios with a robust sample of US payers, then worked with the client to identify a win-win solution.


Our client was able to select a strategy balancing commercial requirements with payer needs.